HB 783: Generally revise health insurance laws relating to certain conditions - Montana

HB0783_2(12).pdf → HB0783_3.pdf · 3 edits

MINOR

The bill was renumbered from HB 783.2 to HB 783.3 and underwent significant text revisions to clarify its title and scope. The most notable substantive change is the specific inclusion of 'Class 3 obesity' in the list of conditions requiring coverage, replacing the broader and less precise term 'obesity.' This ensures the legislation explicitly targets severe obesity, aligning the law with current medical standards and specific drug indications.

Scope change

The bill's scope was narrowed and clarified by specifying 'Class 3 obesity' instead of the general term 'obesity,' ensuring coverage requirements apply specifically to severe obesity cases.

SCOPE

The bill title and summary were updated to explicitly include 'Class 3 obesity' rather than just 'obesity,' clarifying that coverage mandates apply specifically to severe obesity.

TECHNICAL

The bill number was updated from HB 783.2 to HB 783.3, and the list of amended statutes was slightly reordered to reflect the correct section numbers.

DEFINITION

Text was reorganized to better define the relationship between obesity treatment and other conditions like PCOS, ensuring the language accurately reflects FDA-authorized uses for the medications.

HB0783_2(3).pdf → HB0783_2(4).pdf · 4 edits

MODERATE

The bill was amended to expand insurance coverage for specific obesity and reproductive health medications, including GLP-1 receptor agonists for severe obesity and polycystic ovary syndrome (PCOS). It also mandates that these drugs cannot be subject to special cost-sharing requirements like higher deductibles or copayments compared to other medical services. Additionally, the bill includes a requirement for the state to report on the utilization and cost savings of these drugs to legislative committees.

Scope change

The scope of the bill was expanded to include coverage for GLP-1 receptor agonists and PCOS treatment, and the applicability of cost-sharing restrictions was clarified to apply broadly to these medications.

ELIGIBILITY

Added coverage authorization for GLP-1 receptor agonists used to treat Class 3 or higher obesity and polycystic ovary syndrome (PCOS).

REQUIREMENT

Modified cost-sharing rules to prohibit special deductibles, coinsurance, or copayments for the newly covered medications, ensuring they are treated similarly to other medical services.

Added a mandatory reporting requirement for the Department of Administration to submit annual data on drug utilization, costs, and savings to legislative budget committees.

SCOPE

Clarified that the new coverage mandates apply specifically to group health insurance for state and university system employees, excluding disability, hospital indemnity, and long-term care policies.

HB0783_1(5).pdf → HB0783_2.pdf · 4 edits

MODERATE

The bill was significantly rewritten to shift its focus from requiring coverage for diabetes and obesity treatments for the general public to mandating coverage for state and university employees. The new version adds specific reporting requirements for the Department of Administration to track the costs and effectiveness of these treatments for state employees.

Scope change

The bill's scope changed from a broad mandate covering individual and group health insurance policies to a specific mandate applying only to group health insurance for state employees and Montana University System employees.

SCOPE

The bill now applies exclusively to group health insurance for state and university employees, removing the requirement for private insurers to cover obesity and diabetes drugs for the general public.

REQUIREMENT

A new reporting requirement was added, mandating that the Department of Administration report utilization, costs, and cost savings to several legislative committees by September 1 of each year.

DEFINITION

The definition of 'medically necessary' was expanded to explicitly include polycystic ovary syndrome (PCOS) alongside diabetes and class 3 obesity.

ELIGIBILITY

The specific list of covered drugs was updated to specify that glucagon-like peptide-1 receptor agonists are covered for the treatment of class 3 or higher obesity, PCOS, or other FDA-authorized conditions.

HB0783.001.007_combo_final-condensed.pdf → HB0783_1(2).pdf · 5 edits

MODERATE

The bill was significantly restructured to add new coverage for diabetes and obesity treatments while simultaneously updating state employee retirement benefits. The most critical change is the addition of a new section requiring insurance plans to cover glucagon-like peptide-1 receptor agonists for class 3 obesity and polycystic ovary syndrome, provided they are medically necessary. Concurrently, the bill was amended to allow state legislators and judges to remain in their group health plans after leaving office, subject to specific conditions.

Scope change

The bill's scope expanded from solely addressing state employee retirement benefits to include mandatory coverage for specific medical treatments for diabetes, obesity, and polycystic ovary syndrome for all individuals in the state.

ELIGIBILITY

Added a new requirement for all individual and group insurance policies issued in the state to cover glucagon-like peptide-1 receptor agonists for class 3 obesity and polycystic ovary syndrome when medically necessary.

Amended the rules for state legislators and judges to allow them to remain in the state's group health plan after leaving office, provided they notify the department within 90 days and meet specific criteria.

REQUIREMENT

Prohibited insurance plans from imposing special deductibles, coinsurance, or copayments on the newly covered diabetes and obesity medications.

Updated the reporting requirements for the department of administration to include utilization and cost data related to the new diabetes and obesity coverage.

TECHNICAL

Removed references to 'state group insurance' and 'state employees' from the main title and summary, reflecting the broader application of the new medical coverage provisions.

HB0783_1(1).pdf → HB0783.001.007_combo_final-condensed.pdf · 4 edits

MODERATE

The bill was significantly rewritten to shift its focus from mandating coverage for specific diabetes and obesity drugs for the general public to establishing mandatory group health insurance provisions specifically for state employees and university system staff. The original text requiring insurance companies to cover GLP-1 agonists and PCOS treatments was removed and replaced with detailed rules on how state employees can remain on group plans after retirement or death, including specific provisions for judges and legislators.

Scope change

The bill's scope changed from a broad mandate affecting all individual and group health insurance policies in Montana to a narrow mandate applying only to group health insurance plans for state employees and Montana university system employees.

REQUIREMENT

Deleted the requirement for all individual and group health insurance policies to cover GLP-1 receptor agonists for obesity and treatments for polycystic ovary syndrome.

Added a requirement for the Department of Administration to report annually on the utilization, costs, and savings resulting from these new group plan continuation provisions.

SCOPE

Added specific applicability language restricting the bill's mandatory provisions to group health insurance for state employees and Montana university system employees.

ELIGIBILITY

Replaced general coverage mandates with specific eligibility rules allowing state employees, judges, and legislators to remain on group plans after retirement, death, or termination, including new opt-out rights for COBRA coverage.

LC3697.pdf → HB0783_1.pdf · 1 edit

MINOR

The bill was renumbered from LC 3697 to HB 783.1, indicating a change in its legislative status or version. The document title was updated to reflect this new number. No substantive policy changes, such as new requirements, funding amounts, or eligibility criteria, were identified in the provided text.

TECHNICAL

The bill number was changed from LC 3697 to HB 783.1, and the document header was updated to reflect this new identifier.

Generally revise health insurance laws relating to certain conditions

What changed between versions

How they voted

Actions timeline

Sponsors